Kura Oncology (NASDAQ:KURA) Raised to Hold at Wall Street Zen

Kura Oncology (NASDAQ:KURA) was upgraded by investment analysts at Wall Street Zen from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Other equities analysts have also issued reports about the stock. Mizuho decreased their price objective on shares of Kura Oncology from $30.00 to $25.00 and set an “outperform” rating for the company in a research report on Tuesday, March 24th. UBS Group reaffirmed a “buy” rating and issued a $15.00 price objective (down from $16.00) on shares of Kura Oncology in a research report on Friday, March 13th. Zacks Research raised shares of Kura Oncology from a “strong sell” rating to a “hold” rating in a research report on Thursday, February 26th. Wedbush decreased their price objective on shares of Kura Oncology from $38.00 to $36.00 and set an “outperform” rating for the company in a research report on Friday, March 6th. Finally, Lake Street Capital started coverage on shares of Kura Oncology in a research report on Tuesday, April 14th. They issued a “buy” rating and a $23.00 price objective for the company. Ten equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $26.38.

Kura Oncology Stock Performance

KURA stock opened at $9.22 on Friday. The firm has a market cap of $818.46 million, a price-to-earnings ratio of -2.75 and a beta of 0.32. The firm has a 50-day simple moving average of $8.90 and a two-hundred day simple moving average of $9.46. Kura Oncology has a one year low of $5.45 and a one year high of $12.49. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.14 and a current ratio of 6.15.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.05. The firm had revenue of $18.27 million during the quarter, compared to analyst estimates of $25.97 million. Kura Oncology had a negative net margin of 411.19% and a negative return on equity of 141.95%. On average, equities analysts forecast that Kura Oncology will post -3.23 EPS for the current fiscal year.

Hedge Funds Weigh In On Kura Oncology

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Suvretta Capital Management LLC increased its holdings in Kura Oncology by 5.7% in the 4th quarter. Suvretta Capital Management LLC now owns 8,575,422 shares of the company’s stock worth $89,099,000 after buying an additional 459,422 shares during the period. Vanguard Group Inc. increased its holdings in Kura Oncology by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 5,507,627 shares of the company’s stock worth $57,224,000 after buying an additional 39,105 shares during the period. Armistice Capital LLC increased its holdings in Kura Oncology by 5.7% in the 4th quarter. Armistice Capital LLC now owns 4,936,000 shares of the company’s stock worth $51,285,000 after buying an additional 264,000 shares during the period. State Street Corp increased its holdings in Kura Oncology by 47.5% in the 4th quarter. State Street Corp now owns 4,931,090 shares of the company’s stock worth $51,234,000 after buying an additional 1,587,959 shares during the period. Finally, AQR Capital Management LLC increased its holdings in Kura Oncology by 36.6% in the 4th quarter. AQR Capital Management LLC now owns 3,062,212 shares of the company’s stock worth $31,816,000 after buying an additional 820,020 shares during the period.

Key Stories Impacting Kura Oncology

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: Kura emphasized a strong start for KOMZIFTI, noting about $5.8 million in first full launch-quarter sales, which suggests early commercial traction. Kura targets 2028 first top line KOMET-017 Phase III results as KOMZIFTI posts $5.8M in first full launch quarter
• Positive Sentiment: Brokerage commentary remained constructive overall, with Barclays reportedly reiterating a Buy and analysts collectively maintaining a Moderate Buy view. Kura Oncology (KURA) Receives a Buy from Barclays
• Neutral Sentiment: In its Q1 earnings discussion, Kura highlighted the commercial launch of KOMZIFTI and pipeline milestones, including plans for KOMET-017 Phase III topline results in 2028. Kura Oncology Inc (KURA) Q1 2026 Earnings Call Highlights: Strong KOMZIFTI Launch Amid Rising …
• Negative Sentiment: HC Wainwright lowered earnings estimates across several periods, including Q2 2026, Q3 2026, Q4 2026, FY2026, FY2027, FY2028, and FY2029, signaling expectations for deeper losses than previously modeled.
• Negative Sentiment: The most recent revisions were especially notable for FY2026 and FY2027, where projected EPS losses widened, reinforcing concerns that profitability remains distant.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.